Fresenius Medical Care Ag ADR (FMS) Stock Price, Quote & News

Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract...

Industry: Medical Care Facilities

Sector: Healthcare

Phone: 49 6172 609 0

Website: www.freseniusmedicalcare.com

Address:

Else-Kröner-Strasse 1, Bad Homburg, Germany

Noname2022 Jan. 14 at 1:57 AM

$CRMD $FMS https://jpmorgan.metameetings.net/events/healthcare26/sessions/317381-fresenius-medical-care-ag/webcast?gpu_only=true&kiosk=true

1 · Reply

Noname2022 Jan. 13 at 3:03 PM

$CRMD $FMS Fresenius JPM call tomorrow morning Chance for an update on CBRSI reduction initiative mentioned during their Q3 call…

0 · Reply

Noname2022 Jan. 12 at 4:12 PM

$CRMD $FMS

1 · Reply

Noname2022 Jan. 11 at 12:42 AM

$CRMD $AKBA $FMS $DVA

2 · Reply

Noname2022 Jan. 10 at 7:56 PM

$CRMD $FMS

0 · Reply

Noname2022 Jan. 9 at 12:10 PM

$CRMD $FMS $DVA Used ChatGPT to summarize a new CRBSI study comparing catheter types shows catheter choice alone doesn’t solve infections, which keeps lock solutions relevant. https://academic.oup.com/ckj/article/19/1/sfaf392/8381221?login=false#google_vignette

0 · Reply

Noname2022 Jan. 9 at 11:36 AM

$CRMD $FMS Defencath is small but a component of their FMS reignite strategy; good to see strong execution/making money… “Helen Giza, CEO and Chair of the Management Board, said, “The successful acceleration of our EUR 1 billion share buyback program is supported by our strong financial performance and consistent execution against our ‘FME Reignite’ strategy, with a focus on value creation and delivering returns to our shareholders.” https://freseniusmedicalcare.com/en/media/newsroom/fresenius-medical-care-accelerates-the-second-tranche-of-its-eur-1-billion-share-buyback-program-with-around-eur-415-million-repurchase-planned/?utm_source=linkedin&utm_medium=social&utm_campaign=09jan2026_sharebuyback&utm_content=helen_giza

0 · Reply

Noname2022 Jan. 8 at 4:29 PM

$CRMD $AKBA $FMS $DVA

1 · Reply

Noname2022 Jan. 8 at 3:21 AM

$CRMD $FMS Let Joe build…

3 · Reply

Noname2022 Jan. 4 at 9:39 PM

$CRMD $AKBA $DVA $FMS Dr. Pfaffle, Cormedix cofounder

4 · Reply

Fresenius Medical Care AG (FMS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 9, 2026, 7:00 AM EST - 5 days ago

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Dec 10, 2025, 8:00 AM EST - 5 weeks ago

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

Nov 25, 2025, 10:50 AM EST - 7 weeks ago

Fresenius Medical Care: 'Buy' Again Following A Peak In May

Nov 4, 2025, 4:26 PM EST - 2 months ago

Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 2 months ago

Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025

Nov 4, 2025, 1:08 AM EST - 2 months ago

Fresenius Medical Care beats quarterly profit estimates helped by cost cuts

Oct 30, 2025, 9:00 AM EDT - 2 months ago

Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025

Oct 1, 2025, 9:35 AM EDT - 3 months ago

Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement

Sep 18, 2025, 3:30 PM EDT - 4 months ago

Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment

Aug 11, 2025, 7:00 AM EDT - 5 months ago

Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

Aug 5, 2025, 11:23 AM EDT - 5 months ago

Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

Jul 22, 2025, 7:31 AM EDT - 6 months ago

Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)

Jul 18, 2025, 4:25 AM EDT - 6 months ago

$6.3 Trillion Outpatient Clinics Markets, 2021-2024 & 2025-2029 | Profiles of Leading Players - Johns Hopkins Medicine, Mayo Clinic, MD Anderson Cancer Center, Apollo Hospital, and Fresenius Medical

Jul 3, 2025, 8:00 AM EDT - 6 months ago

Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico

Jun 17, 2025, 1:21 PM EDT - 7 months ago

Fresenius Medical Care Launches Value-Based Care Segment, Eyes Growth Through Innovation, Efficiency

Jun 17, 2025, 8:56 AM EDT - 7 months ago

Fresenius Medical Care CEO Says Company Could Benefit From Obesity Drugs

Jun 17, 2025, 7:00 AM EDT - 7 months ago

Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

Jun 17, 2025, 4:08 AM EDT - 7 months ago

Fresenius Medical Care announces 1 bln euros share buyback programme

Jun 16, 2025, 3:06 PM EDT - 7 months ago

5 Stocks To Ride The German Market Rally

BNTX SAP

Jun 4, 2025, 8:00 AM EDT - 8 months ago

Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.

May 30, 2025, 8:00 AM EDT - 8 months ago

Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025

May 22, 2025, 11:45 AM EDT - 8 months ago

Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History

May 8, 2025, 3:08 AM EDT - 8 months ago

Fresenius Medical Care AG (FMS) Q1 2025 Earnings Conference Call Transcript

May 6, 2025, 7:00 AM EDT - 9 months ago

Fresenius Medical Care starts 2025 with strong organic revenue and income growth

May 6, 2025, 1:04 AM EDT - 9 months ago

Fresenius Medical Care tops market expectations in 1st quarter

Apr 9, 2025, 6:32 PM EDT - 9 months ago

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

ABBV AMGN AZN BMY GSK JNJ LLY

Mar 13, 2025, 8:00 AM EDT - 10 months ago

Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum

Mar 4, 2025, 3:57 AM EST - 11 months ago

Fresenius Medical Care's stock falls on Fresenius' stake sale

Feb 25, 2025, 2:59 PM EST - 11 months ago

Fresenius Medical Care AG (FMS) Q4 2024 Earnings Conference Call Transcript

Feb 25, 2025, 7:00 AM EST - 11 months ago

Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

Feb 25, 2025, 1:14 AM EST - 11 months ago

Fresenius Medical Care slightly beats market estimates in fourth quarter

Feb 24, 2025, 8:00 AM EST - 11 months ago

Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

DGX

Jan 31, 2025, 6:20 AM EST - 1 year ago

Fresenius Medical Care: A 'Buy' Going Into 2025

Dec 23, 2024, 9:00 AM EST - 1 year ago

Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index

Dec 20, 2024, 11:23 AM EST - 1 year ago

Fresenius Medical Care returns to Dax 40 Index

Nov 5, 2024, 8:33 PM EST - 1 year ago

Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO

Nov 5, 2024, 2:34 PM EST - 1 year ago

Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:00 AM EST - 1 year ago

Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024

Oct 21, 2024, 11:04 AM EDT - 1 year ago

Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024

Oct 4, 2024, 4:04 PM EDT - 1 year ago

Fresenius Medical Care: Let's Look At The Upside

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software

Jul 30, 2024, 9:30 PM EDT - 1 year ago

Fresenius Medical Care CEO says strategy is working as company delivers on transformation efforts

Jul 30, 2024, 12:39 PM EDT - 1 year ago

Fresenius Medical Care AG (FMS) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024

Jul 13, 2024, 9:16 AM EDT - 1 year ago

US FTC probing DaVita, Fresenius Medical, Politico reports

DVA

Jun 25, 2024, 6:15 AM EDT - 1 year ago

Fresenius Medical Care: Significant Upside Remains

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations

May 23, 2024, 12:33 PM EDT - 1 year ago

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Noname2022 Jan. 14 at 1:57 AM

$CRMD $FMS https://jpmorgan.metameetings.net/events/healthcare26/sessions/317381-fresenius-medical-care-ag/webcast?gpu_only=true&kiosk=true

1 · Reply

Noname2022 Jan. 13 at 3:03 PM

$CRMD $FMS Fresenius JPM call tomorrow morning Chance for an update on CBRSI reduction initiative mentioned during their Q3 call…

0 · Reply

Noname2022 Jan. 12 at 4:12 PM

$CRMD $FMS

1 · Reply

Noname2022 Jan. 11 at 12:42 AM

$CRMD $AKBA $FMS $DVA

2 · Reply

Noname2022 Jan. 10 at 7:56 PM

$CRMD $FMS

0 · Reply

Noname2022 Jan. 9 at 12:10 PM

0 · Reply

Noname2022 Jan. 9 at 11:36 AM

0 · Reply

Noname2022 Jan. 8 at 4:29 PM

$CRMD $AKBA $FMS $DVA

1 · Reply

Noname2022 Jan. 8 at 3:21 AM

$CRMD $FMS Let Joe build…

3 · Reply

Noname2022 Jan. 4 at 9:39 PM

$CRMD $AKBA $DVA $FMS Dr. Pfaffle, Cormedix cofounder

4 · Reply

Noname2022 Jan. 2 at 7:20 PM

$CRMD $AKBA $FMS $DVA new 2026 rates https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ESRDpayment/Downloads/Drugs-and-Biologicals-Eligible-for-TDAPA.pdf

2 · Reply

VictorGayle724 Jan. 2 at 4:51 PM

$AMH $FMS $SMMT $EVR $NDSN Solid insight

0 · Reply

Noname2022 Dec. 30 at 3:51 AM

$CRMD $FMS $DVA Defencath available almost everywhere but NOT at Davita https://evtoday.com/news/cormedix-defencath-evaluated-to-prevent-catheter-related-bloodstream-infections-in-hemodialysis

2 · Reply

Gencooliveoil Dec. 28 at 8:38 PM

$FMS $CRMD $DVA

0 · Reply

InvestorM Dec. 28 at 3:18 PM

$FMS $CRMD $DVA

0 · Reply

Noname2022 Dec. 26 at 6:07 PM

$FMS $CRMD $DVA FMS excited about 25% reduced hospitalizations, wait until they hear about 70% reductions with Defencath! ***DEFENCATH NOT at DAVITA*** “In a large, real-world study, risk for CVD-related hospitalization was 25% lower with hemodiafiltration vs. hemodialysis.”

2 · Reply

Noname2022 Dec. 26 at 12:03 AM

$CRMD $TLPH $FMS

0 · Reply

OfficialStocktwitsUser Dec. 24 at 4:47 PM

$FMS RSI: 62.26, MACD: -0.1026 Vol: 0.35, MA20: 23.55, MA50: 24.54 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Noname2022 Dec. 18 at 6:02 PM

$CRMD $FMS $DVA RWE similar to Phase III lockit trial efficacy This ISPOR paper/model was based on phase III trial and other assumptions https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-4/the-clinical-value-and-cost-effectiveness-of-defencath-for-reducing-catheter-related-bloodstream-infections-in-adult-patients-receiving-hemodialysis-through-a-central-venous-catheter

1 · Reply

InvestorM Dec. 18 at 1:33 PM

$CRMD $DVA $FMS $AKBA

0 · Reply

Noname2022 Dec. 18 at 1:13 PM

$CRMD $DVA $FMS $AKBA “Based on CorMedix’s analysis of the data available through September 30, 2025, compared to historical controls, use of DefenCath demonstrated an overall 72% reduction in CRBSI, and a 70% reduction in hospitalizations secondary to CRBSI.“ https://www.globenewswire.com/news-release/2025/12/18/3207654/0/en/CorMedix-Therapeutics-Announces-Positive-Data-From-Ongoing-Real-World-Evidence-Study-of-DefenCath.html

0 · Reply

Noname2022 Dec. 18 at 8:58 AM

$CRMD $FMS

1 · Reply

Market Cap	13.99B
Revenue (ttm)	20.92B
Net Income (ttm)	582.08M
EPS (ttm)	N/A
PE Ratio	11.09
Forward PE	9.38
Profit Margin	2.78%
Debt to Equity Ratio	0.49

Volume	491,900
Avg Vol	487,836
Day's Range	N/A - N/A
Shares Out	586.83M
Stochastic %K	27%
Beta	0.90
Analysts	Sell
Price Target	$25.80